Biochemical and biological studies of mouse APOBEC3

Journal of Virology

Volumn 88, Issue 7, 2014, Pages 3850-3860

  Nair, Smita ^a   Sanchez Martinez, Silvia ^a,b   Ji, Xinhua ^a   Rein, Alan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DEAMINASE; DEAMINASE; GLUTATHIONE TRANSFERASE MA3 FUSION PROTEIN; HYBRID PROTEIN; NUCLEIC ACID; PROTEIN APOBEC3; UNCLASSIFIED DRUG; VIRUS DNA;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; BINDING AFFINITY; BIOCHEMISTRY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DEAMINATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; INSECT CELL; MURINE LEUKEMIA VIRUS; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; RETROVIRUS; REVERSE TRANSCRIPTION; STRUCTURE ACTIVITY RELATION; VIRION; VIRUS PARTICLE;

ANIMALS; CELL LINE; CYTIDINE DEAMINASE; DNA MUTATIONAL ANALYSIS; GLUTATHIONE TRANSFERASE; HIV-1; INSECTS; LEUKEMIA VIRUS, MURINE; MICE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; VIRUS ASSEMBLY;

EID: 84895434941     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03456-13     Document Type: Article

References (54)

1. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. 2002. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79:285-296. http: //dx.doi.org/10.1006/geno.2002.6718.
2. Harris RS, Liddament MT. 2004. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4:868-877. http://dx.doi.org/10.1038/nri1489.
3. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650. http://dx.doi.org/10.1038/nature00939.
4. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. 2004. Vif overcomes the innate antiviral activity ofAPOBEC3Gby promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279: 7792-7798. http://dx.doi.org/10.1074/jbc.M313093200.
5. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. http://dx.doi.org/10.1126/science.1089591.
6. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809. http://dx.doi .org/10.1016/S0092-8674(03)00423-9.
7. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by humanAPOBEC3Gthrough lethal editing of nascent reverse transcripts. Nature 424:99-103. http://dx.doi.org/10 .1038/nature01709.
8. Browne EP, Littman DR. 2008. Species-specific restriction of apobec3-mediated hypermutation. J. Virol. 82:1305-1313. http://dx.doi.org/10 .1128/JVI.01371-07.
9. Rulli SJ, Jr, Mirro J, Hill SA, Lloyd P, Gorelick RJ, Coffin JM, Derse D, Rein A. 2008. Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J. Virol. 82:6566-6575. http://dx.doi.org /10.1128/JVI.01357-07.
10. Sanchez-Martinez S, Aloia AL, Harvin D, Mirro J, Gorelick RJ, Jern P, Coffin JM, Rein A. 2012. Studies on the restriction of murine leukemia viruses by mouse APOBEC3. PLoS One 7:e38190. http://dx.doi.org/10 .1371/journal.pone.0038190.
11. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31. http: //dx.doi.org/10.1016/S0092-8674(03)00515-4.
12. Derse D, Hill SA, Lloyd PA, Chung H, Morse BA. 2001. Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. J. Virol. 75:8461-8468. http: //dx.doi.org/10.1128/JVI.75.18.8461-8468.2001.
13. Iwatani Y, Takeuchi H, Strebel K, Levin JG. 2006. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 80:5992-6002. http://dx.doi.org/10.1128/JVI .02680-05.
14. Navarro F, Bollman B, Chen H, Konig R, Yu Q, Chiles K, Landau NR. 2005. Complementary function of the two catalytic domains of APOBEC3G. Virology 333:374-386. http://dx.doi.org/10.1016/j.virol .2005.01.011.
15. Crist RM, Datta SA, Stephen AG, Soheilian F, Mirro J, Fisher RJ, Nagashima K, Rein A. 2009. Assembly properties of human immunodeficiency virus type 1 Gag-leucine zipper chimeras: implications for retrovirus assembly. J. Virol. 83:2216-2225. http://dx.doi.org/10.1128/JVI .02031-08.
16. Kelley LA, Sternberg MJ. 2009. Protein structure prediction on the Web: a case study using the Phyre server. Nat. Protoc. 4:363-371. http://dx.doi .org/10.1038/nprot.2009.2.
17. Datta SA, Temeselew LG, Crist RM, Soheilian F, Kamata A, Mirro J, Harvin D, Nagashima K, Cachau RE, Rein A. 2011. On the role of the SP1 domain in HIV-1 particle assembly: a molecular switch? J. Virol. 85: 4111-4121. http://dx.doi.org/10.1128/JVI.00006-11.
18. LaRue RS, Andresdottir V, Blanchard Y, Conticello SG, Derse D, Emerman M, Greene WC, Jonsson SR, Landau NR, Lochelt M, Malik HS, Malim MH, Munk C, O'Brien SJ, Pathak VK, Strebel K, Wain-Hobson S, Yu XF, Yuhki N, Harris RS. 2009. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 83:494-497. http://dx .doi.org/10.1128/JVI.01976-08.
19. Sanville B, Dolan MA, Wollenberg K, Yan Y, Martin C, Yeung ML, Strebel K, Buckler-White A, Kozak CA. 2010. Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove. PLoS Pathog. 6:e1000974. http: //dx.doi.org/10.1371/journal.ppat.1000974.
20. Hakata Y, Landau NR. 2006. Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. J. Biol. Chem. 281: 36624-36631. http://dx.doi.org/10.1074/jbc.M604980200.
21. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH. 2009. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5:e1000330. http://dx.doi.org/10.1371 /journal.ppat.1000330.
22. Huthoff H, Malim MH. 2007. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J. Virol. 81:3807-3815. http://dx.doi .org/10.1128/JVI.02795-06.
23. Wang T, Tian C, Zhang W, Luo K, Sarkis PT, Yu L, Liu B, Yu Y, Yu XF.2007. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol. 81:13112-13124. http://dx.doi.org/10.1128 /JVI.00892-07.
24. Wang T, Tian C, Zhang W, Sarkis PT, Yu XF. 2008. Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. J. Mol. Biol. 375:1098-1112. http://dx.doi .org/10.1016/j.jmb.2007.11.017.
25. Zhen A, Du J, Zhou X, Xiong Y, Yu XF. 2012. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities. PLoS One 7:e38771. http://dx.doi.org/10.1371/journal.pone.0038771.
26. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK. 2004. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279:35822-35828. http://dx.doi.org/10.1074/jbc.M405761200.
27. Bulliard Y, Turelli P, Rohrig UF, Zoete V, Mangeat B, Michielin O, Trono D. 2009. Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. J. Virol. 83:12611-12621. http://dx.doi.org/10.1128/JVI .01491-09.
28. Friew YN, Boyko V, Hu WS, Pathak VK. 2009. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology 6:56. http: //dx.doi.org/10.1186/1742-4690-6-56.
29. Demorest ZL, Li M, Harris RS. 2011. Phosphorylation directly regulates the intrinsic DNA cytidine deaminase activity of activation-induced deaminase and APOBEC3G protein. J. Biol. Chem. 286:26568-26575. http://dx.doi.org/10.1074/jbc.M111.235721.
30. Kopietz F, Jaguva Vasudevan AA, Kramer M, Muckenfuss H, Sanzenbacher R, Cichutek K, Flory E, Munk C. 2012. Interaction of human immunodeficiency virus type 1 Vif with APOBEC3G is not dependent on serine/threonine phosphorylation status. J. Gen. Virol. 93:2425-2430. http://dx.doi.org/10.1099/vir.0.043273-0.
31. Shirakawa K, Takaori-Kondo A, Yokoyama M, Izumi T, Matsui M, Io K, Sato T, Sato H, Uchiyama T. 2008. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif. Nat. Struct. Mol. Biol. 15:1184. http://dx.doi.org/10.1038/nsmb.1497.
32. Chelico L, Pham P, Calabrese P, Goodman MF. 2006. APOBEC3G DNA deaminase acts processively 3'→5' on single-stranded DNA. Nat. Struct. Mol. Biol. 13:392-399. http://dx.doi.org/10.1038/nsmb1086.
33. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR. 2004. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11:435-442. http://dx.doi.org/10.1038/nsmb758.
34. Suspène R, Rusniok C, Vartanian J-P, Wain-Hobson S. 2006. Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res. 34:4677-4684. http://dx.doi.org/10 .1093/nar/gkl555.
35. Hu C, Saenz DT, Fadel HJ, Walker W, Peretz M, Poeschla EM. 2010. The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F. J. Virol. 84:11981-11993. http://dx.doi.org/10 .1128/JVI.00723-10.
36. Chelico L, Prochnow C, Erie DA, Chen XS, Goodman MF. 2010. Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J. Biol. Chem. 285:16195-16205. http://dx.doi.org/10.1074/jbc.M110.107987.
37. Charneau P, Alizon M, Clavel F. 1992. A second origin of DNA plusstrand synthesis is required for optimal human immunodeficiency virus replication. J. Virol. 66:2814-2820.
38. Bishop KN, Holmes RK, Malim MH. 2006. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80:8450-8458. http://dx.doi.org/10.1128/JVI.00839-06.
39. Holmes RK, Malim MH, Bishop KN. 2007. APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci. 32:118-128. http: //dx.doi.org/10.1016/j.tibs.2007.01.004.
40. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, Brown WL, Mansky LM, Gorelick RJ, Harris RS, Engelman A, Pathak VK. 2007. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81:7099-7110. http://dx.doi.org/10 .1128/JVI.00272-07.
41. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, Gronenborn AM, Rouzina I, Williams MC, Musier-Forsyth K, Levin JG. 2007. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35:7096-7108. http://dx.doi.org/10.1093 /nar/gkm750.
42. Chaurasiya KR, McCauley MJ, Wang W, Qualley DF, Wu T, Kitamura S, Geertsema H, Chan DS, Hertz A, Iwatani Y, Levin JG, Musier-Forsyth K, Rouzina I, Williams MC. 2014. Oligomerization transforms human APOBEC3G from an efficient enzyme to a slowly dissociating nucleic acid-binding protein. Nat. Chem. 6:28-33. http://dx.doi.org/10 .1038/nchem.1795.
43. Kolokithas A, Rosenke K, Malik F, Hendrick D, Swanson L, Santiago ML, Portis JL, Hasenkrug KJ, Evans LH. 2010. The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3. J. Virol. 84:10933-10936. http://dx.doi.org/10.1128/JVI .01023-10.
44. Stavrou S, Nitta T, Kotla S, Ha D, Nagashima K, Rein AR, Fan H, Ross SR. 2013. Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex. Proc. Natl. Acad. Sci. U. S. A. 110:9078-9083. http://dx.doi.org /10.1073/pnas.1217399110.
45. Jern P, Stoye JP, Coffin JM. 2007. Role of APOBEC3 in genetic diversity among endogenous murine leukemia viruses. PLoS Genet. 3:2014-2022. http://dx.doi.org/10.1371/journal.pgen.0030183.
46. Nitta T, Lee S, Ha D, Arias M, Kozak CA, Fan H. 2012. Moloney murine leukemia virus glyco-gag facilitates xenotropic murine leukemia virusrelated virus replication through human APOBEC3-independent mechanisms. Retrovirology 9:58. http://dx.doi.org/10.1186/1742-4690-9-58.
47. Low A, Okeoma CM, Lovsin N, de las Heras M, Taylor TH, Peterlin BM, Ross SR, Fan H. 2009. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology 385:455-463. http://dx.doi.org/10.1016/j.virol.2008 .11.051.
48. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, Hasenkrug KJ, Greene WC. 2008. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321:1343-1346. http://dx.doi.org/10.1126/science.1161121.
49. Takeda E, Tsuji-Kawahara S, Sakamoto M, Langlois M-A, Neuberger MS, Rada C, Miyazawa M. 2008. Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J. Virol. 82:10998-11008. http://dx.doi.org/10.1128/JVI.01311-08.
50. Langlois MA, Kemmerich K, Rada C, Neuberger MS. 2009. The Akv murine leukemia virus is restricted and hypermutated by mouse Apobec3. J. Virol. 83:11550-11559. http://dx.doi.org/10.1128/JVI.01430-09.
51. MacMillan AL, Kohli RM, Ross SR. 2013. APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription. J. Virol. 87:4808-4817. http://dx.doi .org/10.1128/JVI.00112-13.
52. Okeoma CM, Huegel AL, Lingappa J, Feldman MD, Ross SR. 2010. APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe 8:534-543. http://dx.doi.org/10.1016/j.chom.2010.11.003.
53. Okeoma CM, Lovsin N, Peterlin BM, Ross SR. 2007. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445:927-930. http://dx.doi.org/10.1038/nature05540.
54. Okeoma CM, Petersen J, Ross SR. 2009. Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J. Virol. 83:3029-3038. http://dx.doi.org/10.1128 /JVI.02536-08.